Mamaearth parent Honasa calls off Fluence Pharma acquisition

GURUGRAM: Two months is not very long to fall out of love with an acquisition, but that is exactly the timeline Honasa Consumer has just run. The company behind Mamaearth has called off its proposed purchase of a 58 per cent stake in Fluence Pharma, the nutraceuticals firm it announced buying with considerable fanfare back on 23rd June. In a stock exchange filing, Honasa said the conditions required to close the deal under its share purchase agreement simply had not been met. It did not spell out which conditions, or whether due diligence had turned up something uncomfortable, but the silence itself is instructive.

What makes this worth a proper look, rather than a shrug, is the discipline on display. The deal was meant to wrap up within eight weeks of announcement. As recently as 13th August, Honasa’s own management told analysts that due diligence was still underway and pre-closing conditions were being worked through, with integration to follow once complete. Barely a fortnight later, the whole thing has been shelved. That is not dithering. That is a company walking away the moment the numbers or the terms stopped adding up, rather than forcing through a transaction for the sake of a press release.

The structure of the original deal is worth remembering, if only to appreciate what Honasa has just avoided getting locked into. The company had proposed buying the initial 58 per cent stake from Fluence’s existing shareholders, with the remaining 42 per cent to follow in two tranches spread over five to seven years. The Rs 135 crore figure represented Fluence’s enterprise value, with the final transaction value subject to closing adjustments, the sort of long-tail, multi-year commitment that can turn into a millstone if the underlying business does not perform as advertised.

Fluence itself is no minnow. Founded by Amit Bhusari and dermatologist Rajendra Singh Rajput, the company sells over-the-counter supplements for hair and skin conditions built around a patented approach it calls Cyclical Nutrition Therapy, administering supplements in a prescribed sequence. It posted provisional revenue of about Rs 40 crore and an operating margin north of 20 per cent in FY26, according to Honasa’s own numbers, with hair-focused products driving more than 70 per cent of revenue through a network of over 3,000 dermatologists. Honasa’s original acquisition presentation had even sketched out plans to build this into a Rs 500 crore nutraceuticals franchise. Those are not the fundamentals of a broken business, which makes the collapse of the deal more about deal terms and closing conditions than about Fluence’s underlying quality.

Crucially, Honasa has been quick to draw a line under any wider anxiety. The company said the cancellation would not alter its nutraceuticals strategy, pointing to Honasa Health, the separate subsidiary it has already set up for the category, which will keep evaluating both in-house product development and further acquisitions. Whether the Rs 500 crore ambition survives Fluence’s exit unscathed remains an open question the company has chosen not to answer yet, but the broader signal is one of a firm that knows what it wants in the nutraceuticals space and is prepared to be patient about how it gets there, rather than settling for the first deal on the table.